[go: up one dir, main page]

HK1210178A1 - Substituted pyridopyrazines as syk inhibitors - Google Patents

Substituted pyridopyrazines as syk inhibitors Download PDF

Info

Publication number
HK1210178A1
HK1210178A1 HK15111133.8A HK15111133A HK1210178A1 HK 1210178 A1 HK1210178 A1 HK 1210178A1 HK 15111133 A HK15111133 A HK 15111133A HK 1210178 A1 HK1210178 A1 HK 1210178A1
Authority
HK
Hong Kong
Prior art keywords
alkyl
optionally substituted
halogen
hydroxy
cycloalkyl
Prior art date
Application number
HK15111133.8A
Other languages
English (en)
Chinese (zh)
Inventor
Wei-Guo Su
Wei Deng
Original Assignee
Hutchison Medipharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50882786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1210178(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Limited filed Critical Hutchison Medipharma Limited
Publication of HK1210178A1 publication Critical patent/HK1210178A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
HK15111133.8A 2012-12-07 2013-12-06 Substituted pyridopyrazines as syk inhibitors HK1210178A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2012/086144 2012-12-07
PCT/CN2012/086144 WO2014086032A1 (fr) 2012-12-07 2012-12-07 Pyridopyrazines substituées utilisées en tant qu'inhibiteurs de syk
PCT/CN2013/088817 WO2014086316A1 (fr) 2012-12-07 2013-12-06 Pyridopyrazines substituées utilisées en tant qu'inhibiteurs de syk

Publications (1)

Publication Number Publication Date
HK1210178A1 true HK1210178A1 (en) 2016-04-15

Family

ID=50882786

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111133.8A HK1210178A1 (en) 2012-12-07 2013-12-06 Substituted pyridopyrazines as syk inhibitors

Country Status (17)

Country Link
US (2) US20150307491A1 (fr)
EP (1) EP2928888A4 (fr)
JP (1) JP6105745B2 (fr)
KR (1) KR20150091169A (fr)
AU (1) AU2013354552B2 (fr)
BR (1) BR112015012825A2 (fr)
CA (1) CA2891725A1 (fr)
CL (1) CL2015001516A1 (fr)
EA (1) EA201590787A1 (fr)
HK (1) HK1210178A1 (fr)
IL (1) IL239153A0 (fr)
MX (1) MX2015007126A (fr)
PE (1) PE20151145A1 (fr)
PH (1) PH12015501175A1 (fr)
SG (1) SG11201503848UA (fr)
TW (1) TW201422616A (fr)
WO (2) WO2014086032A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251565B2 (en) * 2015-04-30 2019-04-09 Dna Medicine Institute, Inc. Multi-channel vitals device
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
CA3036384A1 (fr) 2016-09-14 2018-03-22 Gilead Sciences, Inc. Inhibiteurs de syk
WO2018195471A1 (fr) 2017-04-21 2018-10-25 Gilead Sciences, Inc. Inhibiteurs de syk en association avec des agents d'hypométhylation
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
WO2021080551A1 (fr) 2019-10-21 2021-04-29 Devarasetty Pratyush Pavan Systèmes, dispositifs et procédés de détection de détresse physique chez des nourrissons atteints de trachéostomie
CN115038700B (zh) 2019-11-08 2025-07-25 内尔维亚诺医疗科学公司 偕二取代的杂环化合物及其作为idh抑制剂的用途
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
KR20250007541A (ko) * 2022-04-07 2025-01-14 유니퀘스트 피티와이 리미티드 비장 티로신 키나제 억제제

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008530111A (ja) * 2005-02-14 2008-08-07 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性の阻害剤
TW200942537A (en) * 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
WO2010015520A1 (fr) * 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Naphtyridines substituées et leur utilisation en tant que médicaments
US8604049B2 (en) * 2008-08-05 2013-12-10 Boehringer Ingelheim International Gmbh 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments
CN102574847A (zh) * 2009-07-30 2012-07-11 Irm责任有限公司 作为syk激酶抑制剂的化合物和组合物
BR112012018865A2 (pt) * 2010-01-29 2016-04-12 Boehringer Ingelheim Int naftiridinas substituídas e seu uso como inibidores de quinase syk
WO2012123312A1 (fr) * 2011-03-11 2012-09-20 Glaxo Group Limited Dérivés pyrido[3,4-b]pyrazine en tant qu'inhibiteurs de syk
WO2012167423A1 (fr) * 2011-06-08 2012-12-13 Hutchison Medipharma Limited Pyridopyrazines substituées en tant que nouveaux inhibiteurs de syk

Also Published As

Publication number Publication date
WO2014086316A1 (fr) 2014-06-12
AU2013354552A1 (en) 2015-07-23
MX2015007126A (es) 2015-10-14
EP2928888A1 (fr) 2015-10-14
AU2013354552B2 (en) 2016-09-29
PH12015501175A1 (en) 2015-08-17
PE20151145A1 (es) 2015-08-03
US20150307491A1 (en) 2015-10-29
WO2014086032A1 (fr) 2014-06-12
EA201590787A1 (ru) 2015-11-30
IL239153A0 (en) 2015-07-30
CA2891725A1 (fr) 2014-06-12
JP2016501237A (ja) 2016-01-18
US20160002221A1 (en) 2016-01-07
TW201422616A (zh) 2014-06-16
KR20150091169A (ko) 2015-08-07
CL2015001516A1 (es) 2015-10-23
EP2928888A4 (fr) 2016-04-20
JP6105745B2 (ja) 2017-03-29
BR112015012825A2 (pt) 2017-07-11
SG11201503848UA (en) 2015-06-29
US20170152258A9 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
CN110678466B (zh) 作为hpk1抑制剂的二氮杂萘类
CN107531690B (zh) 用作CBP和/或EP300抑制剂的4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-3-胺化合物
HK1210178A1 (en) Substituted pyridopyrazines as syk inhibitors
DK3083586T3 (en) NEW INDAZOLCARBOXAMIDES, PROCEDURES FOR THE PRODUCTION OF THEM, PHARMACEUTICAL PREPARATIONS CONTAINING THESE AND THEIR USE FOR THE PRODUCTION OF MEDICINAL PRODUCTS
CN112105385A (zh) Irak降解剂和其用途
CN103596952B (zh) 作为Syk抑制剂的新型取代的吡啶并吡嗪类化合物
CN114502158A (zh) Irak降解剂及其用途
CN106715430B (zh) 抑制瞬时型感受器电位a1离子通道
CN105143185B (zh) 嘧啶和吡啶化合物以及它们的用途
WO2020239077A1 (fr) Régulateur dérivé hétérocyclique contenant de l'azote, son procédé de préparation et son application
TWI599562B (zh) 作爲ｔｔｘ－ｓ阻斷劑之醯胺衍生物
TW202116753A (zh) 以噌啉作為hpk1的抑制劑
JP2024505732A (ja) ピリドピリミジノン系誘導体及びその製造方法と使用
TW202038950A (zh) 作為Nav1.7及Nav1.8阻斷劑之雜環衍生物
CN104812755B (zh) 作为ttx‑s阻断剂的吡唑并吡啶衍生物
CN107849044B (zh) 作为ddr1抑制剂的三氮杂-螺癸酮类化合物
CN105884695A (zh) 杂环衍生物类酪氨酸激酶抑制剂
KR20240127910A (ko) Sos1 억제제 및 항암제를 포함하는 암 치료용 약학 조성물
CN104812753A (zh) 作为Syk抑制剂的取代吡啶并吡嗪类化合物
CN111132961A (zh) 作为ttx-s阻断剂的双芳氧基衍生物
HK1190143B (en) Substituted pyridopyrazines as novel syk inhibitors
HK40020685B (en) Naphthyridines as inhibitors of hpk1
HK1248695B (zh) 用作cbp和/或ep300抑制劑的4，5，6，7-四氫-1h-吡唑並[4，3-c]吡啶-3-胺化合物
HK1226409B (zh) 新吲唑甲酰胺、其制备方法、包含其的药物制剂及其用於制备药物的用途